Lonza Expands Strategic Partnership with US Biopharma Leader

Lonza Group AG has announced an expanded collaboration with a leading US biopharmaceutical company, focusing on biologics programs. This expansion is driven by sustained high demand for Lonza's global biologics outsourcing and manufacturing solutions. The partnership enables Lonza to cater to the partner's specific needs with a comprehensive, customizable offering, which includes process intensification and drug manufacturing.

The collaboration supports a diverse clinical and commercial portfolio and offers high flexibility and quick scalability. This long-term partnership comprises multiple contracts with the potential to deliver a multi-billion CHF value over time, reflecting the increasing demand for integrated development and manufacturing services.

Lonza's manufacturing services for this collaboration will operate from its US biologics sites, alongside its European capabilities. This arrangement provides geographic flexibility and security of supply, supporting the partner's long-term growth strategy. Additionally, Lonza will enhance manufacturing process efficiency by using advanced technologies, including N-1 perfusion, which will reduce cycle times.

Gordon Bates, Head of Integrated Biologics at Lonza, emphasized the partnership's commitment to combining cutting-edge science and lean manufacturing. This collaboration demonstrates Lonza’s role as a vital manufacturing partner, empowering its partner to navigate complex portfolios with speed and flexibility.